Related Experiment Videos
DEC1 expression in 1p-aberrant oligodendroglial neoplasms
M Preusser1, P Birner, I M Ambros
1Institute of Neurology, Medical University Vienna, Austria.
Histology and Histopathology
|September 2, 2005
Summary
Differentiated embryo-chondrocyte expressed gene 1 (DEC1) is present in most oligodendroglial tumors but does not indicate hypoxia. DEC1 expression does not correlate with patient outcome in these 1p-aberrant neoplasms.
Area of Science:
- Neuro-oncology
- Molecular pathology
- Cancer research
Background:
- Hypoxia-related factors impact patient outcomes in 1p-aberrant oligodendroglial neoplasms.
- Differentiated embryo-chondrocyte expressed gene 1 (DEC1) is a novel hypoxia-related factor.
- The study investigates DEC1 expression in these tumors.
Purpose of the Study:
- To assess DEC1 expression in 1p-aberrant oligodendroglial neoplasms.
- To determine the association of DEC1 with necrosis and hypoxia markers (HIF-1alpha, CA9, VEGF).
- To evaluate DEC1 as a marker for tissue hypoxia in this tumor type.
Main Methods:
- Immunohistochemistry was used to detect DEC1, HIF-1alpha, and CA9 expression.
- In situ hybridization was employed for VEGF expression analysis.
- Sixty oligodendroglial neoplasms (44 primary, 16 recurrent) with 1p-aberrations were analyzed.
Main Results:
- DEC1 was expressed in tumor cell nuclei and occasionally in endothelial and surrounding brain cells.
- High DEC1 expression was observed in 56 cases, low in 3, and none in 1 case.
- DEC1 expression showed no correlation with necrosis, HIF-1alpha, CA9, or VEGF.
Conclusions:
- DEC1 is expressed in the majority of 1p-aberrant oligodendroglial neoplasms.
- DEC1 expression does not correlate with necrosis or key hypoxia markers (HIF-1alpha, CA9, VEGF).
- Immunohistochemical analysis of DEC1 is not suitable for detecting tissue hypoxia in these primary brain tumors.